Umm, well seeing as they cannot possibly offer a dividend while not making money, his job is not to increase share price. His job is to build the company for success. All it takes is one drug...or a pipeline. They have a pipeline, so all you need is more time.
That very well could be the case. But, then the question becomes when and what will be the trigger for a buyout? The return of B to Array?
Just ask Ron for another CC where he can tell you a million times about the future catalyst. 92% institutional ownership They r keeping a lid on it for the buyout
Yeah, the stock is still stuck in a long-term downtrend. It will take some time for it to base and turn around, but it will happen. It needs more material news regarding Binimetinib, like Novartis returning the drug, new partnerships, new drug discovery/acquisitions, etc. It just needs bigger news.
sounds like positive results. why are we down today? doesn't make sense. while I realize it's Phase 2 but still.
- Median overall survival is encouraging for this patient population -
- Most frequently observed adverse events consistent with MEK inhibitor class -
BOULDER, Colo., Sept. 29, 2014 /PRNewswire/ -- Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented today at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. Invented by Array BioPharma Inc. (NASDAQ: ARRY) and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2.
Results from the 117 patient Phase 2 study showed median progression free survival (mPFS) of 3.6 months and objective response rate (ORR) of 14.5%, including one patient who achieved a complete response. These findings were consistent with previously disclosed interim results at the American Society of Clinical Oncology 2012 annual meeting. In addition, the median overall survival (mOS) of 12.2 months is encouraging for this patient population, which has a particularly poor prognosis. NEMO, a global phase 3 trial currently enrolling patients with NRAS mutant melanoma, is designed to measure the difference in PFS between patients treated with binimetinib versus those treated with dacarbazine, a current standard of care.
Adverse events in the Phase 2 study were generally mild to moderate. The most frequently observed adverse events included acneiform dermatitis, increased blood creatine phosphokinase and peripheral edema, which are consistent with previous results reported for the MEK inhibitor class.
"Patients with NRAS mutations have no targeted treatment available and prognosis is poor," said Reinhard Dummer, M.D., University of Zurich Hospital, Zurich, Switzerland. "These data reinforce our view that binimetinib is an important new potential treatment option for these patients and I look forward to seeing the results from the ongoing Phase 3 NEMO trial to validate these findings."
I'm definitely not taking sides on an anonymous message board, but I don't understand why AstraZeneca's news would be something to post about on ARRY's board.
Agreed if "The Street" believed and trusted CEO RON this would be double digits by now, he wont even spend a dime of his own money to buy any shares on the open market. "MONEY TALKS BS WALKS"
Ron sees advancements in phase studies, presentations at asco etc., as milestone events, the market yawns. The events that might impact share price are way beyond the control of Ron, or anyone at Array. The phase 3 studies at Novartis and Astra if good are 6 and 9 months off and the only true catalysts.
Ron cannot speed that up, it is out of his hands. In fact Novartis could give mek 162 back, Astra could get their mek to the Nda stage, and arry might not rise above 4.00. The share price is up to the market, not the Ceo. Ron when asked about catalysts is obligated to lay out the time line for the pipeline, the market is not rewarding those at all.
The best scenario is two NDA's, but then there will still be no revenue, and the ATM will still be diluting our position. The real catalyst here is REVENUE, and that needs the other catalysts to pan out, and revenue will not happen until 2016. So, flip it for dimes and quarters to make the wait less painful, but this will take MORE time, 6-9 months minimum, 18 months max, with the gamble that phase studies pan out.
REVI enters the cannabis space by announcing plans for the media sector. This news could send the stock soaring towards its 52-wekk high of .31
The closest known possible catalyst is the return of Binimetinib to Array from Novartis. We'll have to see what the price impact is from that event.